Myoblast-mediated gene transfer and its repeated applica-myoblasts, SCID mice stably produced hFIX into the systemic circulation proportional to the number of implanted tions were tested for achieving a long-term stable systemic production of human factor IX (hFIX) at a therapeutic level cells, and the expression levels were maintained for at least up to 10 months (end of the experiment). Additional cell in SCID mice. Primary skeletal myoblasts were stably transfected with a hFIX expression plasmid vector, pdLMe4bA-injections administered to animals that originally received 10 Ì 10 6 cells approximately 2 months later elevated the hIXm1, which contains a hFIX minigene under the control of a b-actin promoter with muscle creatine kinase enhancers. systemic hFIX levels to an average of 182 Ô 21 ng/mL, a therapeutic level, which persisted for at least 8 months (end Myotubes derived from the myoblasts produced 1,750 ng hFIX/10 6 cells/24 hours in culture. hFIX secretion by the of the experiment). These results indicate that long-term, stable systemic production of hFIX at therapeutic levels can myoblasts and thereof derived myotubes were equally efficient, and myotubes were shown to have a sufficient secre-be achieved by repeated application of myoblast-mediated gene transfer. tory capacity to handle a substantially elevated production of hFIX.
H erythropoietin. [19] [20] [21] [22] Recently, we have constructed a series of hFIX expression vectors extensively refined for skeletal EMOPHILIA B is an X-chromosome-linked, recessive bleeding disorder caused by clotting factor IX (FIX) deficiency in the circulation. 1 This disease is currently muscle. These were designed to be easily used either as retroviral or nonviral gene transfer vectors. 23 treated by infusion of FIX protein purified from normal human plasma, which is effective, but exposes patients to po-In the present study, we tested the feasibility of myoblastmediated gene transfer and its repeat application in SCID tential side effects such as hepatitis or human immunodeficiency virus (HIV) infection. More recently, preparation of mice by using primary skeletal myoblasts stably transfected with a refined hFIX expression vector plasmid. We have safer recombinant human FIX (hFIX) has been achieved, and its clinical testing is under way. 2 However, the require-demonstrated that it is feasible to achieve long-term stable systemic production of hFIX at therapeutic levels in the ment of frequent infusions still adversely affects the patient's quality of life, and gene therapy may provide a safe and animals. Some fundamental issues involved in this approach were also studied in vitro. effective alternative treatment for this disease. [3] [4] [5] Most gene transfer approaches tested to date in animals for hemophilia B have used viral vectors such as retrovirus
MATERIALS AND METHODS

and adenovirus for delivering FIX gene into various target
Mouse. Pathogen-free, inbred, male SCID mice 5 to 6 weeks of cells and tissues. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] hFIX expression levels in vivo achieved age were obtained from Taconics (Germantown, NY) and housed in these experiments, however, were either too low to be in a sterile environment in the Unit of Laboratory Animal Medicine therapeutic, [3] [4] [5] [6] [7] [8] [9] or high, but transient as typically shown for facility of this campus. All the animal studies were carried out in adenoviral gene transfer. [10] [11] [12] [13] Some studies using genetically accordance with the institutional guidelines.
Vectors. Construction of the differentiated muscle cell-specific modified cell lines, such as NIH 3T3 cells 15 and C2C12 hFIX expression vector, pdLMe4bAhIXm1, was described elsecells, 16 could give high therapeutic levels of hFIX expression where. 23 It contains a hFIX minigene (hIXm1) with a shortened first in vivo, but the injected cells formed tumors in animals. In intron sequence and a transcriptional control unit composed of a busing retroviral vectors, the possible contamination of helper virus remains to be a safety concern. 17 Adenovirally transferred FIX gene can survive over months and can continue actin promoter (bA) and four copies of muscle creatine kinase gene by ELISA, and its activity was determined by one-stage clotting assay. 25 enhancer (Me4) (Fig 1) . Plasmid vectors pLIXSN (Fig 1) and pBAG Southern blot analyses. Genomic DNA prepared from cells was contain hFIX cDNA and a bacterial b-galactosidase (b-gal) gene, digested with Kpn I or BamHI, and subjected to Southern blot analyrespectively, in retroviral vector frames under the transcriptional sis using 32 P labeled hFIX cDNA as a hybridization probe. 25 The control of the long-terminal repeat (LTR), and a neomycin resistance transgene band intensity was quantified with PhosphorImager (Mogene (Neo) under the control of SV40 promoter. 24, 25 pSV2Neo is a lecular Dynamics, Inc, model 400E). Transgene copy numbers in Neo expression vector 26 and pCH110 is a b-gal expression vector. 27 the genomic DNA were determined by using known amounts of Cells and culture conditions. Mouse primary skeletal myoblasts vector DNA as the copy number standard. were isolated from muscles of SCID mice and grown in growth Analyses of hFIX production and secretion efficiency. Stably medium containing Dulbecco's modified essential medium transfected or retrovirus-transduced cells were plated at a density of (DMEM), 20% fetal calf serum (FCS), 0.5% chicken embryo extract about 6 1 10 5 cells per dish in 6-cm dishes. The media were collected (GIBCO/BRL), and antibiotics (streptomycin and penicillin). 7, 23 daily, and cells were collected for preparing protein extracts and total hFIX assay medium was composed of the growth medium supple-RNA on days 2, 5, and 7. Cellular protein extracts were prepared as mented with BaSO 4 -treated FCS (20%) and Vitamin K1 (10 mg/ previously described 23 except that the extraction solution contained mL). 7, 23 Differentiation medium was the same as the hFIX assay
Complete protease inhibitor (one Complete protease inhibitor tablet medium except that FCS was replaced with BaSO 4 -treated horse per 25 mL) (Boehringer Mannheim). Intracellular and secreted hFIX serum (2%). In all experiments, culture medium was collected every was determined by ELISA. Total cellular RNA was prepared using 24 hours for quantifying hFIX by enzyme-linked immunosorbent TRIzol total RNA isolation reagent (GIBCO-BRL) and subjected to assay (ELISA) as previously described, 7,23 and replaced with fresh Northern blot analysis using hFIX cDNA labeled with 32 P as the medium. Differentiation of myoblasts to myotubes was induced by hybridization probe. The filter was exposed to X-ray films, and changing the medium to the differentiation medium for 3 days. All radioactivity of RNA bands on the filter were quantified by a Phoscells were kept at 37ЊC in a humidized incubator under 5% CO 2 . phorImager (Molecular Dynamics). The filter was then stripped of Transient expression assay of hFIX expression vectors in muscle the hFIX probe and rehybridized with 32 P labeled 18S ribosomal cells. Transient expression assays were carried out using LIPOFECT-RNA cDNA to confirm equal RNA loading to the lanes. AMINE-mediated cell transfection as previously described. 23 Myo-Intramuscular implantation of myoblasts. Myoblasts carrying blasts at a density of 2 1 10 5 per well in 6-well plates were trans-hFIX or b-gal expression vectors were harvested and washed as fected with 2 mg of a hFIX expression vector and 0.2 mg of pCH110 described, 7,28 and resuspended in serum-free DMEM supplemented DNA. Myoblasts in one well from each group were collected at the with 1 mg/mL basic fibroblast growth factor (bFGF) (R&D systems) end of day 2 and were used for determining cell number, b-gal at 50 or 100 1 10 6 cells/mL. Cells were then injected into the limb activity, and total cellular protein content, which were used for normuscles of SCID mice through a 30 G needle at five or ten different malizing the transfection efficiency as previously described. 23 Cell sites (10 mL per site). 7,28 At various time points after cell injection, number at the time of switching to the differentiation medium was blood samples (0.1 to 0.3 mL) were collected by orbital sinus bleedapproximately 2 1 10 6 /well at 80% to 90% confluency.
ing under brief anesthetization with inhalation of methoxyflurane Stable transfection of myoblasts and hFIX expression assay. Pri-(Pitman-Moore) and plasma samples were prepared for ELISA. At mary myoblasts at a density of approximately 1 1 10 6 per 10-cm various time points, animals were killed by deep anesthesia with dish were cotransfected with 10 mg pdLMe4bAhIXm1 and 0.8 mg methoxyflurane. Muscles into which cells were implanted were re-pSV2Neo using LIPOFECTAMINE as described above, and subjected moved for preparing muscle tissue sections and for isolating myoto G418 selection (1 mg/mL). Primary myoblasts transduced with blasts carrying transgenes. The tissue sections were used for H & E LIXSN and BAG retroviruses were prepared as previously destaining and immunohistochemical staining. Myoblasts isolated from scribed. 28 BAG was used as a background control, and LIXSN was the muscle tissue which received cell implantation were subjected used as a hFIX expression reference control because the cells carto G418 selection and used for in vitro hFIX expression assays as rying LIXSN were well characterized in our previous studies for previously described. 28 their in vitro and in vivo hFIX expression and served for assessing Immunostaining analysis. Tissue sections were stained for hFIX any improvements in hFIX expression with the new vector. hFIX using a murine anti-hFIX monoclonal antibody, AHIX-5041 expression levels were determined by plating myoblasts stably trans-(Haematologic Technologies, Inc), and Histostain-SP Kit (Zymed fected with pdLMe4bAhIXm1, or myoblasts transduced with LIXSN Laboratories, Inc) according to the manufacturer's instructions. H & or BAG retrovirus at a density of about 4 1 10 5 cells per well in E and Masson trichrome stain were carried out using standard histologic methods. 29 6-well plates. hFIX protein produced into the medium was quantified For personal use only. on August 31, 2017. by guest www.bloodjournal.org From jected to ELISA screening for hFIX production. Nineteen of them were positive for hFIX expression, and six colonies expressed over 200 ng/10 6 myoblasts/24 hours. Myotubes derived from one of these myoblast colonies produced hFIX at 1,750 { 61 ng/10 6 cells/24 hours on day 6, the highest level among the colonies tested. Myotubes derived from the myoblasts transduced with LIXSN produced 463 { 114 ng hFIX/10 6 cells/24 hours ( Fig 2B) . Southern blot analysis of the genomic DNA indicated that the cells transfected with pdLMe4bAhIXm1 or transduced with LIXSN had approximately four or two copies of the vector DNA per cell, respectively (data not shown). The recombinant hFIX protein produced from myoblasts and myotubes was biologically fully active with a specific activity ranging from 95% to 103% and a molecular size similar to natural hFIX (68 kD), agreeing well with our previous observations (Fig 3) . 16, 25 A minor band with an apparent smaller size (about 52 kD) observed may be a degradation product of hFIX protein generated during the protein preparation procedure as we also observed for canine factor IX. 30 Characterization of production and secretion of hFIX by muscle cells. To test the capacities of primary myoblasts and myotubes in hFIX expression and secretion, hFIX mRNA as well as intracellular and secreted hFIX levels were determined. Following differentiation, intracellular and secreted hFIX levels of cells carrying pdLMe4bAhIXm1 
6 cells/24 hours.
Systemic delivery of hFIX in SCID mice after single and repeated cell implantations. hFIX production into the circulation of SCID mice after myoblast-mediated gene transfer Western blot analysis. hFIX in aliquots (1 mL) of day 5 culture is shown in Fig 6. Five groups of SCID mice (n Å 4 per medium of myotubes was precipitated with barium sulfate (100 mg) group) were implanted with various numbers of primary and subjected to Western blot analysis as previously described 16, 25 using a rabbit anti-hFIX polyclonal antibody and the chemiluminescence Western blot kit (Boehringer Mannheim).
RESULTS
Transient and stable expression of hFIX by muscle cells in vitro.
In vitro hFIX production levels of myoblasts transiently transfected with pdLMe4bAhIXm1 were 6-to 10fold higher than those transfected with pLIXSN ( Fig 2A) . Myotubes carrying pdLMe4bAhIXm1 secreted hFIX at a rate of 212 { 21 ng/10 6 cells/24 hours on day 6, a 15-fold higher level than that of myotubes with pLIXSN (14 { 5 were prepared by cotransfection with pSV2Neo followed by with an approximate size of 52 kD in lanes 1 and 2 may correspond G418 selection. Fifty-three myoblast colonies picked were to degradation products of hFIX during the protein preparation procedure.
individually expanded and their medium samples were sub-For personal use only. on August 31, 2017. by guest www.bloodjournal.org From the original unimplanted, parent cells (Fig 7) . Myoblasts isolated from another animal in group 1 3 months after implantation also gave similar results (data not shown). These results were consistent with our previous observations, 28 demonstrating that a fraction of implanted cells can acquire the satellite cell status, and that little inactivation of LTR or Me4bA promoter took place in vivo. Although it is not likely, the possibility of partial inactivation of these promoters in vivo and regaining of their full activities in vitro cannot be denied. Immunohistochemical analysis of muscle tissue sections prepared from mice in groups 4 and 5 after 200 to 300 days of the original cell implantation also confirmed active hFIX production by the implanted cells (Fig 8, A and  B) .
Characterization of tumor. About 6 months post-cell implantation, one of the group 4 animals developed a tumor in Ô 0.1 ng/10 6 cells and 593.2 Ô 8.9 ng/10 6 cells/24 hours for intracellular (ᮀ) and secreted hFIX () from cells stably transfected with pdLMe4bAhIXm1, 6.2 Ô 2.1 ng/10 6 cells and 581.6 Ô 74.9 ng/10 6 cells/ 24 hours for intracellular (᭺) and secreted hFIX (q) from myoblasts transduced with LIXSN, respectively. Intracellular and secreted hFIX levels of myotubes were normalized to those of myoblasts (day 2), which were defined as 1 as shown on the Y-axis. myoblasts stably carrying BAG, LIXSN, or pdLMe4bA-hIXm1. Animals in groups 1 and 2 were injected with 20 1 10 6 myoblasts transduced with BAG or LIXSN retroviral vectors. Animals in groups 3, 4, and 5 were injected with 5, 10, and 20 1 10 6 myoblasts with pdLMe4bAhIXm1, respectively. As assayed 26 days after the first cell injection, animals in groups 2, 3, and 4 produced hFIX at average levels of 23.1, 27.1, and 58.5 ng/mL serum, respectively. Animals in group 5 gave the highest hFIX production (94.1 ng/mL serum on average), 4-to 5-fold higher than those in group 2, which received myoblasts carrying LIXSN. 7 These results were remarkably consistent with the in vitro observations ( Fig 2B) . hFIX expression levels in groups 3, 4, and 5 were approximately proportional to cell numbers injected ( Fig 6) . Stable hFIX production at levels of approximately 12, 18, and 60 ng/mL serum were observed for groups 2, 3, and 5, respectively, at least up to 10 months (end of observation).
To test the feasibility of repeat cell implantation, animals in group 4 were injected with additional doses of cells on day 43 (10 1 10 6 , left leg muscle), day 52 (10 1 10 6 , right leg muscle), and day 59 (20 1 10 6 , both forearm muscles).
Fig 5. Northern blot analysis of hFIX expressed by myoblasts and
Systemic hFIX levels in these animals were elevated to a cells showed a hFIX expression level equivalent to that of For personal use only. on August 31, 2017. by guest www.bloodjournal.org From Fig 6. hFIX levels in the systemic circulation of SCID mice after intramuscular implantation of myoblasts carrying pdLMe4bAhIXm1 or LIXSN. The background ELISA signals obtained from group 1 (control group) mice, which were injected with 2 Ì 10 7 myoblasts transduced with BAG, were subtracted from the observed levels of other groups. Group 2 mice were injected with 2 Ì 10 7 myoblasts transduced with LIXSN. On day 0, group 3, group 4, and group 5 animals were injected with 5, 10, and 20 Ì 10 6 myoblasts stably transfected with pdLMe4bAhIXm1, respectively. Mice in group 4 were injected with additional cell doses (1, 1, and 2 Ì 10 7 cells, respectively) on days 43, 52, and 59 as shown with arrows. Results from individual animals in each group were shown. Such an increase was invariably observed, when the im-transgene level is presumably due to the presence of a massive tumor tissue interspersed with a lesser amount of the planted primary cells were transformed and proliferated in vivo. Cells isolated from the tumor biopsy expressed only a normal muscle cells carrying the transgene in the muscle tissue removed for various analyses (Fig 8C) . Masson tri-background level of hFIX (less than 10 ng/10 6 /24 hours in culture), and they did not survive the G418 selection. Cells chrome stain ( Fig 8D) 29 and electron microscopic studies (data not shown) identified that this tumor is a fibrosarcoma. isolated from the other leg of the same animal, where the same batch and number of cells were also injected with no These results probably determined that the tumor is not derived from the implanted myoblasts. subsequent tumor development, survived the G418 selection well. The selected cells expressed hFIX at a comparable level with that of the unimplanted parent cells (Fig 7) . South-
myotubes. (A) Total cellular RNAs prepared from cells on day 2 (myoblasts) and day 5 (myotubes) in
DISCUSSION
ern blot analysis detected substantially lowered level (23%)
In recent years, the promising potential of myoblast-mediof the factor IX transgene in the genomic DNA prepared ated gene transfer for systemic production of therapeutic from the tumor tissue in comparison with that of the other proteins has been reported by multiple groups including leg where no tumor developed (Fig 9) . The lowered ours. 3,5-8 In most of these studies, retroviral expression vectors combined with single dose cell implantation were used. In the present study, we have successfully demonstrated that the nonviral myoblast-mediated gene transfer and its repeat application can be used to achieve a long-term stable production of hFIX into the systemic circulation in mice at a therapeutic level. The systemic level achieved in this feasibility study is equivalent to 4% to 5% of the normal hFIX level, sufficient to change a clinically severe hemophilia B to a mild condition. pdLMe4bAhIXm1, one of our refined hFIX expression vectors, 23 was used as a plasmid vector in the present study. In transient assays, this vector, which contains a muscle specific transcription control unit, can express approximately 15-fold higher hFIX than LIXSN (our first generation retroviral vector) in myotubes (Fig 2A) . Myotubes derived from 1 1 10 6 myoblasts stably transfected with this vector produced as high as 1,750 ng of hFIX per 24 hours, approxi- (Fig 2B) . This is a relatively small increase in the original cell implantation. Myoblasts obtained were selected with comparison to that observed in the transient expression G418 and pooled for the analysis. Experimental conditions are similar assays (Ç15-fold) (Fig 2A) . This difference cannot be simply to those in Fig 2B. Averages of triplicate assays are shown with  standard deviations (vertical bars) .
explained by the transgene copy number, because cells trans- fected with pdLMe4bAhIXm1 have approximately four cop-ent myoblasts in accordance with the increased mRNA level, indicating that the myotubes have a secretory capacity suffi-ies of the expression vector per cell, while those transfected with LIXSN have approximately two copies per cell (data cient to handle the elevated hFIX production. These results indicate that hFIX secretion is not the rate limiting step in not shown). Positional effects may be, in part, responsible for the difference, and/or some changes in expression activi-producing hFIX from myotubes (Figs 4 and 5) . Animals injected with various numbers of myoblasts car-ties of the promoters used may possibly take place in the stably integrated transgene environment. Alternatively, the rying pdLMe4bAhIXm1 or LIXSN persistently produced hFIX into the circulation for at least 10 months (end of the difference could be related to possibly poor secretion of hFIX from myotubes. As shown for the LIXSN-transduced experiment) ( Fig 6) . In addition, hFIX levels in the systemic circulation were roughly proportional to the cell numbers cells (Fig 4) , however, myotubes can express and secrete hFIX as efficiently as myoblasts. Furthermore, intracellular injected. Importantly, this repeat cell implantation scheme works well, thus enabling us to achieve much higher, truly as well as secreted hFIX levels observed with myotubes derived from primary myoblasts carrying pdLMe4bAhIXm1 therapeutic levels of stable hFIX production into the circulation (Fig 6, group 4) . The elevated hFIX levels were again are elevated approximately threefold over those of their parapproximately proportional to the total cell number injected. Rando and Blau 31 also reported that, after intramuscular injection of myoblasts transduced with the b-gal expression retroviral vector, the expression levels of b-gal are proportional to the injected cell numbers in a given range. The cell numbers as well as cell concentration used by Rando and Blau, 31 however, were much smaller than those used in the present study. The hFIX levels in the systemic circulation reported here were 10-to 15-fold higher than the stable levels we previously achieved in mice, 7 and much higher than those (approximately 10 ng/mL of canine FIX in mice) reported by Dai et al, 8 who also used an approach of primary myoblast-mediated gene transfer with retroviral vectors. Kay peated therapies are important.
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From Based on the two-compartment distribution kinetics, 16, 32 or primary myoblasts, which are transduced with recombinant retroviruses, invariably developed rhabdomyosarcomas we have estimated that the plasma hFIX concentration level obtained for the group 4 animals is less than 5% of the after 60 days of cell implantation. Unfortunately, the investigators provided neither information regarding the potential theoretical steady-state level that could be expected with the total 5 1 10 7 cells injected. Here we assume that all cells contamination of replication-competent retrovirus in the viral stock used nor other explanations for the tumor development can produce hFIX in vivo as efficiently as in vitro. Although it is a rough estimation, this suggests that most implanted with the primary myoblasts.
The present study has demonstrated the feasibility to refine cells are not efficiently contributing to hFIX production in vivo. This may be due to (1) the death of a large percentage the myoblast-mediated gene transfer method in achieving both the long-term systemic production of therapeutic level of the implanted cells without successful fusion with existing myofiber cells or among themselves to form new myofiber recombinant FIX and improved safety. The results warrant further intensive studies on its safety aspects and improve-cells, (2) the in vivo environment is substantially different from that in the culture and the transgene cannot be ex-ment of the overall FIX systemic production, before its clinical application. pressed as efficiently as in the cultured cells, (3) a combination of these possibilities, or (4) other yet unknown mecha-ACKNOWLEDGMENT nisms. Generally low survival of nongenetically modified myoblasts implanted in humans (the above second possibil-We thank Dr David L. Allen and Dr Ataç Türkay for their critical reading of the manuscript and the morphology core facility of the ity) was also reported by multiple groups 6,33,34 suggesting Reproductive Science Program of the University of Michigan for that the myoblast implantation procedure and cell fusion preparing tissue sections.
processes are at least two critical steps that need further careful investigation for improving this gene transfer ap- 
